WeVote
Log In

Bill

Bill

S 4664

Directs the commissioner of health to conduct a study on the use of ibogaine as a treatment for post-traumatic stress disorder

2025 Regular Session Introduced by Jake Ashby and 1 co-sponsor

Directs NJ Dept of Health to study ibogaine as a PTSD treatment; findings could shape policy, safety guidelines, funding, and patient access.

REFERRED TO HEALTH
0
WeVote Research Nonpartisan
Bill Summary · S 4664

Summary of S 4664 (New Jersey)

Overview

Bill S 4664, introduced on June 26, 2025, is titled: “Directs the commissioner of health to conduct a study on the use of ibogaine as a treatment for post-traumatic stress disorder.” The bill has been referred to the Health committee for consideration.

Purpose

  • The central objective is to require the New Jersey Department of Health to conduct an official study on ibogaine as a treatment option for post-traumatic stress disorder (PTSD).
  • The bill would likely seek to assess the potential clinical efficacy, safety considerations, and policy implications of ibogaine for PTSD, with findings to be reported back to the Legislature. (Note: specific study scope, methodology, funding, and reporting requirements are not detailed in the provided text.)

Key Provisions (as stated)

  • Directs the commissioner of health to study ibogaine as a PTSD treatment.
  • Referred to the Health committee for evaluation and recommendation before any floor action.
  • No dollar figures, study deadlines, or reporting deadlines are specified in the information provided.

Important caveat: The “Introduced Version” text included with this bill package appears to be misaligned with the bill’s stated purpose. The introduced content describes a different measure about filling vacancies in the U.S. House of Representatives. Readers should consult the official bill text for the precise provisions, scope, and requirements of S 4664.

Affected Parties

  • New Jersey Department of Health (lead agency responsible for conducting the study).
  • Individuals with PTSD and potential patients considering ibogaine as a treatment option.
  • Medical professionals, researchers, and clinical trial stakeholders.
  • State policymakers and legislators evaluating PTSD treatment options and regulatory pathways.

Procedural and Timeline Aspects

  • Introduced: June 26, 2025.
  • Status: REFERRED TO HEALTH (Health Committee) — a standard step that precedes potential committee amendments, hearings, and floor consideration.
  • Related legislative items:
    • Companion bill: A 5886.
    • Prior-session: S 8807.
  • Sponsors: Primary sponsor Jake Ashby; Co-sponsor Nathalia Fernandez.

Potential Impact and Considerations

  • Policy Impact: If enacted, the study could inform future state policy on the regulation, funding, and clinical guidance related to ibogaine for PTSD.
  • Research and Safety: The study would need to address safety concerns, dosing considerations, potential adverse effects, and interactions with other PTSD treatments.
  • Access and Equity: Depending on findings, the state could consider recommendations affecting accessibility, healthcare coverage, and patient education.
  • Timing and Resources: The bill’s passage would depend on committee deliberations; a study could require funding, external experts, and coordination with medical institutions.

Note for Readers

Given the apparent mismatch between the bill’s title/purpose and the text labeled as its “Introduced Version,” readers should verify the official NJ Legislature text for S 4664 to confirm the exact provisions, scope, timelines, and reporting requirements before relying on this summary.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.